Published in Nat New Biol on October 03, 1973
Intracellular relationships of the oestrogen receptor in the rat uterus and hypothalamus during the oestrous cycle. Biochem J (1978) 1.38
Estrogen-related increases in uterine guanosine 3':5'-cyclic momophosphate levels. Proc Natl Acad Sci U S A (1974) 1.32
Phosphoprotein phosphatase activity associated with estrogen-induced protein in rat uterus. Proc Natl Acad Sci U S A (1974) 0.78
Separation of "estrogen-induced" protein from phosphoprotein phosphatase activity of immature rat uterus. Proc Natl Acad Sci U S A (1975) 0.75
Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol (1988) 3.92
Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther (1994) 1.79
Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation (1998) 1.73
Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res (2000) 1.70
Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int J Cancer (2000) 1.33
Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res (1986) 1.24
Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol (2005) 1.22
Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett (2000) 1.15
Neonatal problems of late and moderate preterm infants. Semin Fetal Neonatal Med (2012) 1.12
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer (1993) 1.10
Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol (1996) 1.09
Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant (2009) 1.07
Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol (2007) 1.06
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene (2011) 0.99
Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer (2001) 0.99
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant (2005) 0.98
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Ann Oncol (2006) 0.94
90K (Mac-2 BP) in human milk. Clin Exp Immunol (1996) 0.94
Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res (1995) 0.93
Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer. Int J Cancer (1996) 0.91
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. J Acquir Immune Defic Syndr (1993) 0.90
Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein in HIV-1-infected children. J Clin Immunol (2000) 0.90
Biochemistry of cervical mucus: a comparative analysis of the secretion from preovulatory, postovulatory, and pregnancy periods. Fertil Steril (1971) 0.90
Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol (2012) 0.89
Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol (2004) 0.89
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. AIDS Res Hum Retroviruses (1993) 0.89
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. Br J Cancer (2010) 0.89
Antiproliferative effects of somatostatin and the somatostatin analog SMS 201-995 on three human breast cancer cell lines. J Cancer Res Clin Oncol (1988) 0.88
Unknown primary tumors. Biochim Biophys Acta (2011) 0.88
Human milk 90K (Mac-2 BP): possible protective effects against acute respiratory infections. Clin Exp Immunol (1999) 0.88
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. Int J Cancer (1998) 0.88
The effect of parenteral nitrogen and energy intake on electrolyte balance in the preterm infant. Eur J Clin Nutr (2011) 0.88
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. Blood (2000) 0.88
Epidermal growth factor receptor expression in gynecological malignancies. Gynecol Obstet Invest (1989) 0.88
Two new estrogen-supersensitive variants of the MCF-7 human breast cancer cell line. Breast Cancer Res Treat (1983) 0.87
Early low-dose hydrocortisone in very preterm infants: a randomized, placebo-controlled trial. Neonatology (2006) 0.87
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. Br J Cancer (1993) 0.87
Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. Cancer Res (1991) 0.86
Increased tolerability of bimonthly 12-hour timed flat infusion 5-fluorouracil/irinotecan regimen in advanced colorectal cancer: A dose-finding study. Oncol Rep (2006) 0.85
Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study. Oncol Rep (2010) 0.85
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Br J Haematol (1993) 0.85
90K (Mac-2 BP) predicts CD4 decline in human immunodeficiency virus-infected patients with CD4 counts above 200 x 10(6) cells/L. Arch Pathol Lab Med (1998) 0.84
Sequential administration of recombinant human interleukin-2 and dacarbazine in metastatic melanoma: a multicenter phase II study. J Clin Oncol (1991) 0.84
Recombinant alpha-2b-interferon dynamic test as a potential tool in predicting disease status during second look in ovarian cancer. A preliminary report. Cancer (1991) 0.84
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. J Infect Dis (1991) 0.84
PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites. Oncogene (2001) 0.83
Recombinant alpha-2b-interferon enhances the circulating levels of a 90-kilodalton (K) tumor-associated antigen in patients with gynecologic and breast malignancies. Cancer (1990) 0.83
Effects of type-I and -II interferons on 90K antigen expression in ovarian carcinoma cells. Int J Cancer (1994) 0.83
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. Cancer Lett (1996) 0.82
Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (2013) 0.82
Biochemical changes during progesterone-induced maturation in Xenopus laevis oocytes. Mol Cell Biochem (1974) 0.82
Glucocorticoid receptors predict response to combination chemotherapy in patients with acute lymphoblastic leukemia. Oncology (1987) 0.82
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. Cancer (1993) 0.82
Tyrosine kinase inhibitors. Curr Cancer Drug Targets (2010) 0.82
Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol (1999) 0.81
Expression of the 90K immunostimulator gene is controlled by a promoter with unique features. J Biol Chem (1997) 0.81
High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients. Cancer Treat Rep (1987) 0.81
Immunohistochemical localization of creatine kinase BB in primary breast cancer: correlation with estrogen receptor content. J Cancer Res Clin Oncol (1988) 0.81
Glucocorticoids inhibit the stimulatory effect of epidermal growth factor on the initiation of DNA synthesis. J Cell Physiol (1981) 0.80
Predictive value of multiple tumor marker assays in second-look procedures for ovarian cancer. Gynecol Oncol (1989) 0.80
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. Am J Gastroenterol (1995) 0.80
The immune stimulatory protein 90K increases major histocompatibility complex class I expression in a human breast cancer cell line. Biochem Biophys Res Commun (1996) 0.80
Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. Anticancer Res (1988) 0.80
Estrogen responsive creatine kinase in normal and neoplastic cells. J Steroid Biochem (1981) 0.80
Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family. Clin Exp Immunol (1998) 0.79
Temporal trend in the level of 90K glycoprotein after HIV seroconversion among persons coinfected with hepatitis C virus. Infection (2005) 0.79
Isolation and functional characterization of the human 90K promoter. Genomics (1999) 0.79
Discussion about switch strategy in the adjuvant hormonal therapy of breast cancer: psychological aspects of physician-patient communication. Ann Oncol (2009) 0.79
Estrogen stimulates cell proliferation and the increase of a 52,000 dalton glycoprotein in human breast cancer cells. J Steroid Biochem (1984) 0.79
Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol Lett (2009) 0.79
The gene (LGALS3BP) encoding the serum protein 90K, associated with cancer and infection by the human immunodeficiency virus, maps at 17q25. Cytogenet Cell Genet (1995) 0.79
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. J Infect Dis (1991) 0.78
Growth promoting influences of estradiol, epidermal growth factor, and insulin on human breast cancer: evidence for differential mechanism of action on tumor cells in vitro. Breast Cancer Res Treat (1985) 0.78
Effect of thyroid hormones on androgen responsiveness in a mammary tumor cell line. J Steroid Biochem (1981) 0.78
Phosphoprotein phosphatase activity associated with estrogen-induced protein in rat uterus. Proc Natl Acad Sci U S A (1974) 0.78
Immunohistochemical expression of c-erbB-2 in human breast cancer by monoclonal antibody: correlation with lymph node and ER status. Tumori (1990) 0.78
Presence and steroid inducibility of glutamine synthetase in human leukemic cells. J Steroid Biochem (1983) 0.78
Glucocorticoid receptor determinations in leukemia patients using cytosol and whole-cell assays. Cancer Res (1981) 0.78
Growth inhibitory effect of LH-RH analogs on human breast cancer cells. Anticancer Res (1988) 0.78
Estrogen binding by neoplastic human thymus cytosol. Eur J Cancer (1980) 0.78
Role of stem cell transplantation in myeloma. Hematology (2005) 0.78
Elevated levels of circulating immunostimulatory 90K in Henoch-Schoenlein purpura. J Clin Immunol (1999) 0.77
Original technique for preoperative preparation of patients and intraoperative localization of parathyroid adenomas. G Chir (2015) 0.77
Advanced breast cancer: response to somatostatin. Anticancer Res (1990) 0.77
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. Int J Oncol (1997) 0.77
Effects of antiestrogen and progestin on immune functions in breast cancer patients. Cancer (1988) 0.77
The biosynthesis of triiphosphoinositide by purified myelin of peripheral nerve. J Neurochem (1969) 0.77
Immunohistochemical and serological 90K/Mac-2BP detection in hepatocellular carcinoma patients: different behaviour of two monoclonal antibodies. Med Chem (2005) 0.77
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. Anticancer Res (1990) 0.77
Clinical diagnostic clues in Crohn's disease: a 41-year experience. ISRN Gastroenterol (2012) 0.76
Clinical implications of glucocorticoid receptor studies in childhood acute lymphoblastic leukemia. Blood (1980) 0.76
Identification of the tumor antigen 90K domains recognized by monoclonal antibodies SP2 and L3 and preparation and characterization of novel anti-90K monoclonal antibodies. Biochem Biophys Res Commun (1997) 0.76
Characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. Adv Prostaglandin Thromboxane Leukot Res (1995) 0.76
Lack of mother-to-child HIV-1 transmission is associated with elevated serum levels of 90 K immune modulatory protein. AIDS (2000) 0.76
Discrepancies between in vivo and in vitro effects of glucorticoids in myelomonocytic leukemic cells with steroid receptors. Cancer Res (1978) 0.76
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. Oncol Rep (1994) 0.76
Relationship between the tumour-associated antigen 90K and cytokines in the circulation of persons infected with human immunodeficiency virus. J Infect (1994) 0.75
Megestrol acetate plus alpha 2a interferon as second line therapy for postmenopausal patients with advanced breast cancer: results of a multicentric phase II trial. Breast Cancer Res Treat (1995) 0.75
Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer. Br J Cancer (1992) 0.75